ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tegoprazan

Also written as “Tegoprazan”, “Tegoprazan 50 mg” and “BLI5100”.

Its studies are mostly in Esophagitis · Non-Erosive Reflux Disease · Gastroesophageal Reflux · Peptic Ulcer · Duodenal Ulcer, led by 4 companies.

Drug pageTegoprazan: every studyAll 62 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 13, 202048 company-led studies, 7 open or runningNext primary completion: Jan 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
HK inno.Nits history only376 open or runningphase 4since Mar 13, 2020Nov 14, 2011Jan 31, 2027phase 1 · NCT07853248
Shandong Luoxin Pharmaceutical Group Stockits history only70 open or runningphase 3since Jul 9, 2018Jan 25, 2018none ahead
Sebela Pharmaceuticals30 open or runningphase 3since Oct 17, 2022Oct 17, 2022none ahead
Carnot Laboratoriesits history only11 open or runningphase 4since May 20, 2025May 20, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sebela Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2015Named tegoprazanINNProposed as its International Nonproprietary Name in WHO's List 113 · before, BLI5100
  2. Oct 17, 2022First studies: 2 phase 3 studiesFirst studyNCT05587322, NCT05587309
  3. May 5, 2023Phase 3 study in Non-Erosive Reflux DiseaseNCT05890001 · 400 enrolled · United States

TargetBeta

ATP4A →ATP4B →read by rule
“Potassium-transporting ATPase blocker”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
EsomeprazoleruleAstraZenecaphase 4129
RabeprazoleruleEisaiphase 466
OmeprazoleruleAstraZenecaphase 456
vonoprazanruleTakedaphase 448
fexuprazanruleDaewoong Pharmaceuticalphase 429

Studies

All 3 Sebela Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05890001Non-Erosive Reflux Disease · United States3CompletedOct 8, 2024400
NCT05587322Non-Erosive Reflux Disease · United States3CompletedOct 13, 2023788
NCT05587309Erosive Esophagitis · United States3CompletedJun 16, 20251,250

How it is read

Names in the registry

  • “Tegoprazan”, 10 entries
  • “Tegoprazan 50 mg”, 5 entries
  • “BLI5100”, 3 entries
  • “Tegoprazan 50mg”, 3 entries
  • “CJ-12420 50mg”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.